Repertoire Immune Medicines Secures FDA Fast Track Designation for Innovative Cancer Treatment#United_States#Cambridge#RPTR-1-201#Repertoire_Immune_Medicines#fast_track_designation
Repertoire Immune Medicines Secures FDA Fast Track Designation for Innovative Cancer Treatment
Repertoire Immune Medicines has received FDA Fast Track Designation for RPTR-1-201, a promising treatment for triple-negative breast cancer, enhancing its development process.
third-news.com
May 7, 2026 at 12:37 PM
Repertoire Immune Medicines Secures FDA Fast Track Designation for Innovative Cancer Treatment#United_States#Cambridge#RPTR-1-201#Repertoire_Immune_Medicines#fast_track_designation